Walter M. Stadler to Carcinoma, Transitional Cell
This is a "connection" page, showing publications Walter M. Stadler has written about Carcinoma, Transitional Cell.
Connection Strength
3.231
-
Management of Urothelial Bladder Cancer: Predicting the Future. J Oncol Pract. 2019 08; 15(8):429-430.
Score: 0.620
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.356
-
A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol. 2005 May-Jun; 23(3):150-4.
Score: 0.231
-
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002 Jul-Aug; 7(4):153-7.
Score: 0.190
-
Gemcitabine doublets in advanced urothelial cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 3):15-9.
Score: 0.184
-
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000 May; 18(9):1921-7.
Score: 0.163
-
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 1999 Feb; 53(2):243-50.
Score: 0.150
-
Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer. 2018 06 15; 124(12):2507-2514.
Score: 0.142
-
Expression of bcl-2 and bcl-X in bladder cancer. J Urol. 1998 Apr; 159(4):1348-53.
Score: 0.141
-
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997 Nov; 15(11):3394-8.
Score: 0.137
-
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 12; 14(6):511-517.
Score: 0.123
-
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
Score: 0.108
-
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701.
Score: 0.104
-
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6.
Score: 0.082
-
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009 Sep 15; 115(18):4110-7.
Score: 0.078
-
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1339-44.
Score: 0.074
-
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008 Mar; 6(1):31-5.
Score: 0.070
-
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):150-4.
Score: 0.063
-
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol. 2005 Apr; 28(2):109-13.
Score: 0.057
-
Acute bilateral abducens paralysis due to oxaliplatin. J Natl Cancer Inst. 2003 Mar 19; 95(6):488-9.
Score: 0.050
-
Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 1998 Jan 15; 12(2):163-74.
Score: 0.035
-
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 1996 Oct; 156(4):1280-5.
Score: 0.032
-
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996 Aug; 156(2 Pt 1):363-7.
Score: 0.031
-
Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 1995 Feb 01; 55(3):493-7.
Score: 0.007